Milo Biotechnology is a clinical-stage company developing therapies to strengthen muscle in patients with neuromuscular diseases. Its lead program is a gene-therapy approach that uses a version of the protein follistatin to address muscle atrophy associated with muscular dystrophies. The program is based on clinical expertise originating from Columbus’ Nationwide Children’s Hospital. Milo intends to use recently raised funds to prepare for multi-center pivotal clinical trials, which could begin in late 2017. The company was founded in 2012 by Al Hawkins and Brian Kaspar and is based in Cleveland, Ohio. The announcement did not disclose operating metrics or the amount raised. Milo Biotechnology is a Cleveland, OH-based clinical-stage startup developing an adeno-associated virus (AAV) delivered follistatin protein to stimulate muscle growth and prevent muscle scarring. Pre-clinical studies in mice and non-human primates demonstrated considerable increases in muscle size and strength. The company received FDA approval of the investigators' IND in October 2011. A Phase I/II clinical trial evaluating safety and efficacy began in January 2012 at Nationwide Children's Hospital, where the technology was developed. The trial is funded by a grant from Parent Project Muscular Dystrophy and is enrolling patients with Becker muscular dystrophy and inclusion body myositis. Milo was founded by CEO Al Hawkins and Brian Kaspar, PhD.

Total raised

$0M

Funding rounds

2

Latest round

Equity

Latest activity

Feb 2012